ZimVie Inc
NASDAQ:ZIMV

  • LAST PRICE
    14.4150
  • TODAY'S CHANGE (%)
    0.2450 (1.7290%)
  • Bid / Lots
    14.4000/ 2
  • Ask / Lots
    14.4300/ 3
  • Open / Previous Close
    14.2700 / 14.1700
  • Day Range
    14.1700
    14.5500
  • 52 Week Range
    9.0000
    22.4000
  • Volume
    77,409

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 30, 2024

      Show headlines and story abstract

    • 4:53PM ET on Wednesday Oct 30, 2024 by MT Newswires
      Companies Mentioned: ZIMV
      04:53 PM EDT, 10/30/2024 (MT Newswires) -- ...

    • 4:53PM ET on Wednesday Oct 30, 2024 by MT Newswires
      Companies Mentioned: ZIMV
      04:53 PM EDT, 10/30/2024 (MT Newswires) -- ...

    • 4:15PM ET on Wednesday Oct 30, 2024 by MT Newswires
      Companies Mentioned: ZIMV
      04:15 PM EDT, 10/30/2024 (MT Newswires) -- ...

    • 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: ZIMV
      Restructuring and other cost reduction initiatives ([1]) 687 1,391 3,664 3,929 Acquisition, integration, divestiture and related ([2]) 1,276 1,936 6,934 4,647 Related party gain - - - (5) European Union medical device regulation ([3]) 406 295 1,118 2,227 Other charges ([4]) 287 293 860 864 Adjusted EBITDA $ 13,094 $ 12,198 $ 41,547 $ 36,206 ======= ======= ======= ======= Net Loss Margin ([5]) -3.0% -9.7% -7.1% -9.4% Adjusted EBITDA Margin ([6]) 12.7% 11.6% 12.3% 10.5% [1] Restructuring activities to better position our organization for future success based on the current business environment and sale of the spine business. [2] Acquisition, integration, divestiture and related expenses for the three and nine months ended September 30, 2024 include professional services fees ($1.9 million and $5.8 million, respectively) and stranded costs ($0.4 million and $0.9 million, respectively) related to sale of the spine segment, partially offset by fair value adjustment benefit of the seller note related to the sale of the spine segment ($1.2 million and $0, respectively). Acquisition, integration, divestiture and related expenses for the three and nine months ended September 30, 2023 include professional services fees ($1.6 million and $3.2 million, respectively), rebranding costs related to the separation from our former parent ($0.3 million and $0.5 million, respectively) and technology costs ($0 and $0.7 million, respectively) incurred to prepare for and complete the separation from our former parent. [3] Expenses incurred for initial compliance with the EU MDR for previously-approved products. [4] Inventory write-offs resulting from restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions. [5] Net Loss Margin is calculated as Net Loss divided by third party net sales for the applicable period. [6] Adjusted EBITDA Margin is Adjusted EBITDA divided by third party net sales for the applicable period.

    • 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: ZIMV
      Restructuring and other cost reduction initiatives ([1]) 687 1,391 3,664 3,929 Acquisition, integration, divestiture and related ([2]) 1,276 1,936 6,934 4,647 Related party gain - - - (5) European Union medical device regulation ([3]) 406 295 1,118 2,227 Other charges ([4]) 287 293 860 864 Adjusted EBITDA $ 13,094 $ 12,198 $ 41,547 $ 36,206 ======= ======= ======= ======= Net Loss Margin ([5]) -3.0% -9.7% -7.1% -9.4% Adjusted EBITDA Margin ([6]) 12.7% 11.6% 12.3% 10.5% [1] Restructuring activities to better position our organization for future success based on the current business environment and sale of the spine business. [2] Acquisition, integration, divestiture and related expenses for the three and nine months ended September 30, 2024 include professional services fees ($1.9 million and $5.8 million, respectively) and stranded costs ($0.4 million and $0.9 million, respectively) related to sale of the spine segment, partially offset by fair value adjustment benefit of the seller note related to the sale of the spine segment ($1.2 million and $0, respectively). Acquisition, integration, divestiture and related expenses for the three and nine months ended September 30, 2023 include professional services fees ($1.6 million and $3.2 million, respectively), rebranding costs related to the separation from our former parent ($0.3 million and $0.5 million, respectively) and technology costs ($0 and $0.7 million, respectively) incurred to prepare for and complete the separation from our former parent. [3] Expenses incurred for initial compliance with the EU MDR for previously-approved products. [4] Inventory write-offs resulting from restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions. [5] Net Loss Margin is calculated as Net Loss divided by third party net sales for the applicable period. [6] Adjusted EBITDA Margin is Adjusted EBITDA divided by third party net sales for the applicable period.

Peers Headlines